See how equipment leasing helps biotech startups hit milestones faster by preserving cash flow, cutting upfront costs, and accelerating R&D timelines.
Excedr covers Predicta Biosciences’ $23.4M raise to advance liquid biopsy diagnostics for multiple myeloma, replacing painful bone marrow biopsies with blood-based testing.
Axon Therapies pioneers a breakthrough in heart failure treatment with splanchnic nerve ablation—Excedr covers this major biotech funding round.
Star Therapeutics advances antibody therapies for rare blood disorders—Excedr covers this major biotech funding round.
Avenzo Therapeutics raises $60M Series B to advance next-gen cancer therapies—Excedr covers this major biotech funding round announcement.
See what investors look for in lab equipment leasing strategies—and how biotech startups can signal discipline, flexibility, and milestone focus.
Discover why biotech startups choose equipment leasing over buying—preserving cash flow, staying flexible, and aligning lab strategy with milestones.
How do preclinical biotech startups scale faster with equipment leasing? By preserving cash, reducing upfront costs, allowing them to hit milestones sooner.
Ollin Biosciences launches with $100M Series A to develop breakthrough vision therapies—Excedr covers this major biotech funding round announcement.
What types of lab equipment are needed to support AI-driven drug discovery? Learn how to scale smartly with flexible, cost-effective procurement strategies.
